Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

por Tanaka, Hidekazu, Hirata, Michinari, Shinonome, Satomi, Wada, Toru, Iguchi, Motofumi, Dohi, Keiji, Inoue, Makiko, Ishioka, Yukichi, Hojo, Kanji, Yamada, Tomomi, Sugimoto, Tatsuya, Masuno, Koichi, Nezasa, Ken-ichi, Sato, Norihito, Matsuo, Kenji, Yonezawa, Shuji, Frenkel, Eugene P, Shichijo, Michitaka
Publicado 2014